M&A / Property
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Pre-revenue psychedelic-adjacent biotech secures CAD $2M financing and GMP manufacturing partner for BETR-001 IND filing.
Executive Summary
- BetterLife Pharma announced a strategic agreement with Syner-G BioPharma Group to oversee GMP manufacturing of its lead candidate, BETR-001, supporting the path to an IND filing and Phase 1 clinical trials.
- BETR-001 is a non-hallucinogenic LSD derivative (2-Br-LSD) targeting chronic cluster headaches and migraines, designed to avoid 5-HT2B agonism to eliminate hallucinogenic and cardiac side effects.
- The company is completing final IND-enabling studies and projects an IND filing and Phase 1 initiation in Q1 2027.
- BetterLife also engaged GTM Studios for marketing materials at $4,000 per month and issued a correction clarifying the exercise price of 3,250,000 stock options granted on June 15, 2026, as $0.07.
- This announcement follows the closing of a CAD $2 million convertible debenture financing on June 22, 2026, subscribed by a director and insider, which will fund the remaining IND-enabling work and general working capital.
Material Impact
- The partnership with Syner-G validates the company's ability to secure third-party CMC expertise, a critical step for FDA IND submission.
- The CAD $2 million debenture provides immediate liquidity to execute the IND-enabling plan and extend the cash runway, directly addressing the previously disclosed critically tight balance sheet.
- The timeline shift to Q1 2027 is a modest delay from prior late-2026 guidance but remains within a realistic window for GMP manufacturing setup and regulatory submission.
- The news does not alter the fundamental pre-revenue, high-burn nature of the business, nor does it de-risk clinical or regulatory outcomes. It is an expected operational milestone funded by a necessary capital raise.
BETR · Price
Company Overview
- BetterLife Pharma Inc. is a pre-revenue biotechnology company focused on developing neurological and antiviral therapeutics.
- Its lead candidate, BETR-001, is a proprietary, non-hallucinogenic derivative of LSD (2-bromo-LSD) targeting chronic cluster headaches and migraines. It acts as a neuroplastogen and 5-HT2A/1B/1D/1F agonist while avoiding 5-HT2B to prevent hallucinations and cardiac risks.
- The company also holds candidates for viral infections (MM-001/MM-003) and maintains a USPTO composition-of-matter patent for BETR-001.
- The business model relies entirely on external funding to advance clinical development, with no commercial products or revenue streams currently active.
More from BetterLife Pharma Inc.
Jun 22, 2026 · 08:01